Clinical trials: BCC
Carcinoma, Basal Cell (BCC)
Investigation of the Safety and Tolerability of BSCT (Anti-nf-P2X7) 10% Ointment
This is a Phase 1, open-label, single-arm, multicenter study to assess the safety and tolerability of BSCT (anti-nf-P2X7) 10% Ointment in subjects with BCC.
- Trial name
- NCT02587819
- Testing
- Treatment with BSCT
- Volunteers
- 21 people
- Sponsor
- Biosceptre
Head and Neck Cancer, Mucositis Oral
GM-CSF Mouthwash for Preventing and Treating Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer
GM-CSF may protect normal cells from the side effects, such as mucositis, of radiation therapy and may help damaged tissue heal faster after radiation therapy.
- Conditions
- Head and Neck Cancer, Mucositis Oral, Radiation Toxicity, Tongue Cancer
- Trial name
- NCT00293462
- Testing
- sargramostim, oral salt and soda mouthwash
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Marilyn Dodd
Basal Cell Carcinomas
Vismodegib in Basal Cell Carcinomas (BCC) Chemoprevention
This study is a single site double blinded Phase II study to evaluate the chemopreventative effectiveness of vismodegib in the treatment of subjects at high risk for developing basal cell carcinomas (BCC).
- Trial name
- NCT02067104
- Testing
- Vismodegib
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Arizona
Superficial Basal Cell Carcinoma
Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
The purpose of this study is to determine the safety and tolerability of pharmaceutical compound (API 31510) topical cream topically applied to superficial basal cell carcinomas to obtain preliminary efficacy data for the…
- Trial name
- NCT00604890
- Testing
- API 31510 3% Topical Cream, API 31510 1.5% Topical Cream
- Where
- 11 sites in United States
- Volunteers
- 186 people
- Sponsor
- BPGbio
Treatment for Basal Cell Carcinomas (BCCs) in Gorlin Syndrome Patients
A Trial to Evaluate the Safety, Local Tolerability, Pharmacokinetics and Pharmacodynamics of LDE225 on Skin Basal Cell Carcinomas in Gorlin Syndrome Patients
Part I was a double-blind, randomized, vehicle-controlled Proof of Concept (PoC) study to evaluate the safety, local tolerability, pharmacokinetics and pharmacodynamics of multiple topical administrations of LDE225 (a specific…
- Trial name
- NCT00961896
- Testing
- Vehicle, LDE225 0.25%, LDE225 0.75%
- Where
- 3 sites in Austria, Switzerland
- Volunteers
- 18 people
- Sponsor
- Novartis Pharmaceuticals
Basal Cell Carcinoma of the Skin, Recurrent Skin Cancer
Vismodegib in Treating Patients With Basal Cell Carcinoma (BCC)
The purpose of this study is to learn about the effect of vismodegib on sporadic basal cell carcinoma (BCCs) prior to surgical removal.
- Trial name
- NCT01631331
- Testing
- vismodegib, Mohs surgery
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Stanford University
Basal Cell Carcinoma
Evaluation of Efficacy of Photodynamic Therapy in Basal Cell Carcinoma
The purpose of this study is to evaluate the efficacy of pdt in treatment of bcc and factors that affect response rate.
- Trial name
- NCT00985829
- Testing
- photodynamic therapy
- Volunteers
- 28 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Basal Cell Carcinoma
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma
This was a 3-cohort, open-label study of vismodegib (GDC-0449) in new (non-recurrent) operable basal cell carcinoma of the nodular subtype.
- Trial name
- NCT01201915
- Testing
- Vismodegib
- Where
- 12 sites in United States
- Volunteers
- 74 people
- Sponsor
- Genentech, Inc.
Basal Cell Carcinoma
A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma
This study assessed the efficacy and safety of oral treatment with two dose levels of LDE225 in patients with locally advanced or metastatic BCC.
- Trial name
- BOLT (NCT01327053)
- Testing
- LDE225
- Where
- 62 sites in United States, Australia and 10 more
- Volunteers
- 230 people
- Sponsor
- Novartis Pharmaceuticals
Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer
The goal of this study is to learn if giving cemiplimab and vidutolimod together could be effective in treating advanced cancer.
- Conditions
- Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma, Triple Negative Breast Cancer
- Trial name
- NCT04916002
- Testing
- vidutolimod, cemiplimab
- Where
- 24 sites in United States, Australia
- Volunteers
- 77 people
- Sponsor
- Regeneron Pharmaceuticals
Head and Neck Cancer
Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00509665
- Testing
- doxorubicin hydrochloride, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Medical University of South Carolina
Basal Cell Carcinoma
A Study of Vismodegib With Surgery in Participants With Previously Untreated Basal Cell Carcinoma
This randomized, double-blind, placebo-controlled study will assess the efficacy and safety of vismodegib with surgery in participants with basal cell carcinoma.
- Trial name
- NCT01898598
- Testing
- Vismodegib
- Where
- 21 sites in United States
- Volunteers
- 18 people
- Sponsor
- Hoffmann-La Roche
Ovarian Cancer, Basal Cell Carcinoma
A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study
This was a multicenter, open-label extension study. Patients who received vismodegib (GDC-0449) in a Genentech-sponsored study and who had completed the parent study or who continued to receive vismodegib at the time the parent…
- Conditions
- Ovarian Cancer, Basal Cell Carcinoma, Metastatic Colorectal Cancer
- Trial name
- NCT00959647
- Testing
- Vismodegib, FOLFOX, FOLFIRI
- Where
- 10 sites in United States
- Volunteers
- 19 people
- Sponsor
- Genentech, Inc.
Basal Cell Nevus Syndrome
Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)
This is a multicenter, open label extension study evaluating the safety of Patidegib Topical Gel, 2%, applied topically twice daily to the face of adult subjects with Gorlin syndrome.
- Trial name
- NCT04308395
- Testing
- Patidegib Topical Gel, 2%
- Where
- 37 sites in United States, Belgium and 7 more
- Volunteers
- 108 people
- Sponsor
- Sol-Gel Technologies, Ltd.
Basal Cell Nevus Syndrome
Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)
This is a global, multicenter, randomized, double-blind, stratified, vehicle-controlled study of the efficacy and safety of Patidegib Topical Gel, 2%, applied topically twice daily to the face of adult participants with Gorlin…
- Trial name
- NCT03703310
- Testing
- Patidegib Topical Gel, 2%, Patidegib Topical Gel, Vehicle
- Where
- 49 sites in United States, Belgium and 8 more
- Volunteers
- 174 people
- Sponsor
- Sol-Gel Technologies, Ltd.
Basal Cell Carcinoma
Long-pulsed 1064 nm Nd:YAG Laser Treatment of Basal Cell Carcinoma
Basal cell carcinoma (BCC) is the most common skin cancer worldwide. Although this tumor is rarely life threatening, it is locally destructive and can cause significant cosmetic and functional problems.
- Trial name
- NCT02662244
- Testing
- Nd:YAG laser
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of California, San Diego
Basal Cell Carcinoma
Study Evaluating the Efficacy of Oral Vismodegib in Various Histologic Subtypes
The purpose of this study is to investigate the safety and effectiveness of oral vismodegib therapy in the treatment of different 'histologic subtypes' of basal cell skin cancer (BCC).
- Trial name
- NCT01700049
- Testing
- vismodegib (150 mg PO daily)
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Mayo Clinic
BCC, BCC - Basal Cell Carcinoma
Use of Jet-injection in Photodynamic Therapy for Basal Cell Carcinoma
The purpose of this study is to find out whether injecting ALA into the skin with a jet-injection device and activating the drug with light is a safe treatment that causes few or mild side effects in people with basal cell…
- Conditions
- BCC, BCC - Basal Cell Carcinoma, Basal Cell Carcinoma, Basal Cell Cancer
- Trial name
- NCT04552990
- Testing
- Jet injection of ALA, Surgical excision, Illumination
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Basal Cell Carcinoma (BCC)
Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy
The aim of this study is to test the effectiveness and safety of the medicine Ameluz® (5-aminolevulinic acid) in comparison to methyl-aminolevulinate (MAL), used with photodynamic therapy (PDT), to treat thin, non-aggressive BCC…
- Trial name
- NCT02144077
- Testing
- BF-200 ALA, methyl-aminolevulinate
- Where
- Germany
- Volunteers
- 281 people
- Sponsor
- Biofrontera Bioscience GmbH
Melanoma (Skin), Squamous Cell Carcinoma
Using MC1R Genotype to Impact Melanoma Risk Behavior
The purpose of this study is to examine how different messages about risk of melanoma can impact the way people protect themselves against developing these diseases.
- Conditions
- Melanoma (Skin), Squamous Cell Carcinoma, Squamous Cell Cancer, Skin Cancer
- Trial name
- NCT03509467
- Testing
- Personalized Information, Standard Information, DNA Extraction Determination of MC1R Genotypes
- Where
- 2 sites in United States, Puerto Rico
- Volunteers
- 2,054 people, healthy volunteers welcome
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute